Methods for treatment of polycystic kidney disease
US-2024141350-A1 · May 2, 2024 · US
Methods and compositions for treatment of polycystic kidney disease
US12559750B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12559750-B2 |
| Application number | US-202519052052-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 12, 2025 |
| Priority date | Oct 8, 2021 |
| Publication date | Feb 24, 2026 |
| Grant date | Feb 24, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
First claim
Opening claim text (preview).
What is claimed is: 1 . A modified oligonucleotide having the structure: or a pharmaceutically acceptable salt thereof. 2 . The modified oligonucleotide of claim 1 , wherein the pharmaceutically acceptable salt is a sodium salt. 3 . A modified oligonucleotide having the structure: 4 . A pharmaceutical composition comprising the modified oligonucleotide of claim 1 and a pharmaceutically acceptable diluent. 5 . The pharmaceutical composition of claim 4 , wherein the pharmaceutically acceptable diluent is an aqueous solution. 6 . The pharmaceutical composition of claim 5 , wherein the aqueous solution is a saline solution. 7 . A pharmaceutical composition comprising a modified oligonucleotide of claim 2 and a pharmaceutically acceptable diluent. 8 . The pharmaceutical composition of claim 7 , wherein the pharmaceutically acceptable diluent is an aqueous solution. 9 . The pharmaceutical composition of claim 8 , wherein the aqueous solution is a saline solution. 10 . A pharmaceutical composition comprising a modified oligonucleotide of claim 3 and a pharmaceutically acceptable diluent. 11 . The pharmaceutical composition of claim 10 , wherein the pharmaceutically acceptable diluent is an aqueous solution. 12 . The pharmaceutical composition of claim 11 , wherein the aqueous solution is a saline solution. 13 . A pharmaceutical composition comprising a modified oligonucleotide of claim 1 , which is a lyophilized composition. 14 . A pharmaceutical composition comprising a modified oligonucleotide of claim 2 , which is a lyophilized composition. 15 . A pharmaceutical composition comprising a modified oligonucleotide of claim 3 , which is a lyophilized composition.
Assignees
Inventors
Classifications
5-Methylcytosine · CPC title
2'-R Modification · CPC title
2'-O-R Modification · CPC title
Phosphorothioates · CPC title
targeting other non-coding nucleic acids, e.g. antagomirs · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12559750B2 cover?
- Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
- Who is the assignee on this patent?
- Regulus Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification C12N15/113. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 24 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).